Can You Get Mounjaro For Weight Loss Without Diabetes? - Guide | Cured Pharmacy

Can You Get Mounjaro For Weight Loss Without Diabetes?

WEIGHT LOSS · 23 MIN READ
Written by Cured Pharmacy
Published on 18 August 2026
★★★★★ Judge.me Reviews
Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From£145.00£124.99 UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment → ✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 18 August 2026

If you have been watching the news, scrolling through social media, or simply chatting with friends lately, you have almost certainly heard about Mounjaro. It is the injection that everyone seems to be talking about, and for very good reason. But one question keeps coming up again and again in pharmacies, GP waiting rooms, and online forums across the UK: can you get Mounjaro for weight loss without diabetes? The short answer is yes, you absolutely can, but there is a bit more to it than simply requesting a prescription. This article breaks down everything you need to know, from eligibility criteria and how the drug works, to what kind of weight loss results you can realistically expect and where to access it safely in the UK right now.

Summary

Mounjaro (tirzepatide) is now licensed in the UK specifically for chronic weight management in adults without type 2 diabetes, provided they meet certain BMI and health criteria. As of 2026, access has expanded considerably through both NHS and regulated private routes.

  • Mounjaro is approved by the MHRA for weight loss in non-diabetic adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition.
  • Clinical trials showed participants lost up to 22.5% of their body weight over 72 weeks, making it one of the most effective weight loss treatments ever studied.
  • You do not need a diabetes diagnosis to qualify, but you do need a proper clinical assessment from a registered prescriber.
  • Private online pharmacies such as Cured Pharmacy offer safe, regulated access with UK-based prescribers, discreet delivery, and competitive pricing.
  • Use the discount code FIRST20 to save £20 off your first Mounjaro order at Cured Pharmacy.

Table of Contents

What Is Mounjaro and How Does It Work?

Mounjaro BMI Eligibility Checker

Enter your details below to check whether your BMI may meet the standard eligibility threshold for Mounjaro in the UK. This is for guidance only and is not a medical assessment.

This tool is for informational purposes only. Always complete a full clinical consultation before starting any medication.

Mounjaro is the brand name for tirzepatide, a novel injectable medication manufactured by Eli Lilly. What makes it genuinely different from older weight loss drugs is its dual mechanism of action. It activates two receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Most people have heard of GLP-1 receptor agonists like semaglutide, which is found in Wegovy weight loss injections. Mounjaro goes one step further by also targeting GIP receptors, which appears to produce significantly greater weight loss than GLP-1 agonism alone.

In practical terms, Mounjaro works by slowing gastric emptying (meaning food stays in your stomach longer and you feel fuller for more time), reducing appetite signals in the brain, improving insulin sensitivity, and influencing how the body stores and uses fat. It is given as a once-weekly subcutaneous injection using a pre-filled KwikPen, and the dose is gradually increased over several weeks to allow the body to adjust and to minimise side effects such as nausea.

The medication was originally developed for the management of type 2 diabetes, and it was approved for that indication first. However, clinical data on its effects on body weight was so striking that Eli Lilly pursued a separate regulatory pathway for obesity treatment. The MHRA granted approval in the UK specifically for chronic weight management in adults who do not necessarily have diabetes, which is the key point most people want to understand.

Can You Get Mounjaro for Weight Loss Without Diabetes?

Yes. This is one of the most frequently searched health questions in the UK right now, and the answer is an unambiguous yes. The MHRA approved Mounjaro under the brand name Mounjaro for weight management in adults with obesity or overweight in November 2023. This approval is entirely separate from its use in type 2 diabetes, meaning you do not need a diabetes diagnosis to be eligible for a prescription.

The confusion arises because Mounjaro was initially launched in the UK exclusively for patients with type 2 diabetes. For a period, many clinicians and online services would only prescribe it in that context. However, since the weight management licence was granted and NICE published updated guidance, access has expanded meaningfully. In 2026, it is now far more straightforward for eligible adults without diabetes to access this treatment through both NHS specialist services and regulated private providers.

It is worth noting that there is a subtle but important distinction between the licensed indication and NHS commissioning. The NHS has historically been more cautious about rolling out weight management treatments at scale due to supply and budget constraints. NICE guidance published in 2024 recommended Mounjaro as a cost-effective option for use within specialist weight management services, which means access through NHS pathways can still be limited or involve waiting lists. This is precisely why many people choose to access it through regulated private pharmacies, where clinically appropriate prescribing is still subject to robust UK regulatory oversight, but the waiting time is significantly reduced.

  • You do not need type 2 diabetes to qualify for Mounjaro in the UK.
  • The MHRA licence for weight management was granted in November 2023 and covers non-diabetic adults.
  • NHS access exists but may be subject to waiting lists and specialist referral.
  • Private access via regulated online pharmacies provides a legal, safe, and faster route for eligible patients.
  • A prescriber must still assess your suitability before any prescription is issued, regardless of the route you choose.

Who Qualifies? BMI, Health Conditions, and UK Eligibility Criteria

Not everyone can simply request Mounjaro and receive it. The licensed eligibility criteria for using Mounjaro for weight management are clearly defined and are based primarily on BMI and the presence or absence of at least one weight-related health condition. Understanding these criteria before you start your journey will save you time and ensure you are pursuing a route that is appropriate for your situation.

The standard eligibility thresholds are as follows. A BMI of 30 kg/m² or above qualifies on its own, regardless of whether you have any other health conditions. A BMI of 27 kg/m² or above also qualifies, but only if it is accompanied by at least one weight-related comorbidity. These comorbidities include conditions such as hypertension (high blood pressure), dyslipidaemia (abnormal cholesterol or triglyceride levels), obstructive sleep apnoea, cardiovascular disease, or prediabetes. Importantly, type 2 diabetes itself is not listed as a requirement; it simply may appear as one of the eligible comorbidities if present.

There are also certain contraindications and cautions that a prescriber will assess. Mounjaro is not suitable for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It is also not recommended during pregnancy or breastfeeding. Anyone with a history of pancreatitis should have a careful risk-benefit discussion with their clinician. The prescriber will also consider your current medication list, particularly if you are taking other drugs that affect blood glucose, such as insulin or sulfonylureas, because combining these with tirzepatide requires careful dose adjustment.

  • BMI of 30 or above: eligible without any additional health conditions.
  • BMI of 27 to 29.9: eligible only with at least one weight-related health condition.
  • Not suitable if you have a personal or family history of medullary thyroid cancer.
  • Not suitable during pregnancy or breastfeeding.
  • Ethnicity-adjusted BMI thresholds may apply for South Asian, Black, and some other ethnic groups, where a lower BMI may indicate higher metabolic risk.

One frequently overlooked point is ethnicity-adjusted BMI thresholds. NICE guidance and clinical practice in the UK increasingly recognises that South Asian, Black African, and Black Caribbean individuals may carry greater metabolic risk at lower BMI values. Some clinicians therefore apply lower thresholds of 27.5 or 25 for certain ethnic groups, meaning more people may qualify than the headline figures suggest. Always discuss your full health history with a prescriber to ensure the criteria are applied appropriately to your circumstances.

What Weight Loss Results Can Non-Diabetic Patients Expect?

This is where the clinical data becomes genuinely extraordinary. The SURMOUNT-1 trial, which is the pivotal phase 3 study that examined tirzepatide specifically in people with obesity or overweight without type 2 diabetes, produced results that surprised even seasoned researchers. Participants taking the 15 mg dose of tirzepatide lost an average of 22.5% of their body weight over 72 weeks. To put that in context, someone weighing 100 kg could expect to lose approximately 22.5 kg on average, and many participants lost considerably more. No other approved weight loss medication has achieved results anywhere near this level in clinical trials.

The SURMOUNT-1 trial also showed that approximately 91% of participants in the highest dose group achieved at least 5% weight loss, which is the clinical threshold considered meaningful for improving obesity-related health conditions. Around 57% achieved 20% or more weight loss. These are not cherry-picked anecdotes; they are rigorously controlled trial results published in the New England Journal of Medicine and scrutinised by the MHRA before licensing.

In terms of real-world experience, patients and clinicians across the UK have broadly reported results consistent with trial data, though individual variation is significant. Factors such as adherence to dietary changes, physical activity levels, baseline metabolic rate, and how consistently the injections are administered all influence outcomes. Most people starting Mounjaro can expect to notice appetite changes within the first few weeks, with meaningful weight loss typically becoming visible from around weeks four to eight onwards.

  • Average weight loss of 22.5% over 72 weeks in the SURMOUNT-1 trial at the highest dose.
  • Results are significantly greater than those achieved with older GLP-1 medications alone.
  • 91% of participants achieved at least 5% weight loss at the 15 mg dose.
  • Results are enhanced by combining treatment with dietary and lifestyle modifications.
  • Individual results vary; a clinical assessment helps set realistic, personalised expectations.

For those comparing options, it is also worth knowing how Mounjaro compares to semaglutide-based treatments. If you are weighing up weight loss injection options, the data consistently suggests that tirzepatide produces greater average weight reduction than semaglutide, though both are highly effective and both are legitimate, regulated choices in the UK.

How to Access Mounjaro for Weight Loss in the UK

There are currently two main pathways for accessing Mounjaro for weight loss in the UK: through the NHS and through regulated private providers. Understanding the differences between these pathways will help you make an informed decision about which route is most appropriate for your situation.

The NHS route involves referral to a specialist weight management service, which in most areas means your GP would need to refer you. NICE technology appraisal guidance TA1026 recommends tirzepatide for adults who meet the eligibility criteria within specialist services. However, NHS access is subject to local commissioning decisions and waiting lists, which in some areas can be considerable. NHS prescriptions would be subject to standard prescription charges or free for eligible groups, which is a significant cost advantage if you can access this route.

The private route, through regulated online pharmacies and independent prescribers, provides faster access for those who meet the clinical criteria. This route involves completing a detailed online health questionnaire, which is reviewed by a UK-registered prescriber (typically a doctor or pharmacist prescriber). If approved, the medication is dispensed by a GPhC-registered pharmacy and delivered to your home. The prescribing process still adheres to UK clinical standards, meaning it is not simply a case of selecting what you want from a menu; the prescriber exercises genuine clinical judgement.

  • NHS route: GP referral to specialist weight management service, subject to local commissioning and waiting times.
  • Private route: Online consultation with UK-registered prescriber, GPhC-regulated pharmacy, typically faster access.
  • Both routes require clinical assessment; no legitimate provider will supply Mounjaro without one.
  • Always verify that any online pharmacy you use is registered with the GPhC and displays the EU common logo on their website.
  • Private prescriptions for Mounjaro typically start from around £124.99 per month at reputable providers in 2026.

It is extremely important to avoid unregulated sources. Mounjaro being sold without a prescription, through social media, or from unverified overseas suppliers is not only illegal but genuinely dangerous. Counterfeit or substandard tirzepatide products have been identified in the UK by the MHRA, and using such products carries serious health risks. Stick to providers registered with the GPhC and Care Quality Commission.

Why Choose Cured Pharmacy for Mounjaro?

Cured Pharmacy has established itself as one of the most trusted regulated online pharmacies in the UK for weight management treatments. If you are looking for a service that combines clinical rigour with genuine patient care and transparent pricing, Cured Pharmacy is consistently one of the strongest options available.

The consultation process at Cured Pharmacy is thorough. You complete a detailed medical questionnaire that is reviewed by a UK-based prescriber with genuine clinical expertise. This is not a rubber-stamping exercise; if you do not meet the eligibility criteria, you will not be approved. This protects patients and ensures that Mounjaro is only supplied to those for whom it is clinically appropriate. The pharmacy holds GPhC registration and operates under UK regulatory oversight throughout the entire process, from consultation to dispensing to delivery.

In terms of pricing, Cured Pharmacy offers Mounjaro from £124.99, which represents genuine value in the private market. The free private prescription, discreet packaging, and UK-based delivery mean you receive everything you need without unnecessary complexity or expense. For new patients, using discount code FIRST20 at checkout saves you £20 off your first order, making your first month of treatment more accessible financially. This kind of transparent pricing and patient-centred approach is something Cured Pharmacy takes seriously, and it shows in the feedback from patients who return month after month.

Cured Pharmacy also stocks a broad range of weight management support products alongside Mounjaro, meaning you can build a comprehensive, personalised approach to your health journey all in one place. The team is available to answer clinical queries, and the service is designed to feel supportive rather than transactional.

  • GPhC-registered, fully regulated UK online pharmacy with transparent clinical processes.
  • Mounjaro available from £124.99 with free private prescription included.
  • UK-based prescribers review every application with genuine clinical care.
  • Discreet delivery direct to your door with no unnecessary delays.
  • New patient discount: use code FIRST20 to save £20 off your first order.

Mounjaro vs Other Weight Loss Options: A Comparison

Treatment Active Ingredient Average Weight Loss Administration Non-Diabetic Use UK Availability (2026)
Mounjaro Tirzepatide Up to 22.5% of body weight Once-weekly injection Yes, MHRA licensed NHS (specialist) & private
Wegovy Semaglutide 2.4 mg Up to 15% of body weight Once-weekly injection Yes, MHRA licensed NHS (specialist) & private
Ozempic Semaglutide 1 mg Up to 6-7% of body weight Once-weekly injection Not licensed for weight loss Diabetes only on NHS
Orlistat (Xenical/Alli) Orlistat Up to 5-7% of body weight Oral capsule three times daily Yes NHS & OTC pharmacy
Lifestyle modification only N/A Typically 3-5% of body weight Diet and exercise Yes Widely available

As the table illustrates clearly, Mounjaro stands out for its exceptional average weight loss figures compared to all other available options. That said, no treatment works in isolation. Lifestyle changes, nutritional support, and regular monitoring all contribute to sustained success. Many patients also find it helpful to address nutritional gaps during weight loss treatment. Speaking with a clinician about whether general health supplements or specific vitamins might support your journey is always worthwhile, particularly as reduced appetite can sometimes lead to lower intake of key micronutrients.

Key Takeaways

  • You can get Mounjaro for weight loss without diabetes in the UK, provided you meet the BMI and health criteria set out in the MHRA licence and NICE guidance.
  • Mounjaro works via a dual GLP-1 and GIP mechanism that produces significantly greater average weight loss than older GLP-1-only medications.
  • Eligibility requires a BMI of 30 or above, or 27 or above with a weight-related health condition; a proper clinical assessment is mandatory regardless of the route you choose.
  • Clinical trial data (SURMOUNT-1) demonstrated average weight loss of 22.5% at the highest dose, making this one of the most effective treatments in the history of obesity medicine.
  • Cured Pharmacy provides safe, regulated private access to Mounjaro from £124.99, with UK-based prescribers, discreet delivery, and the discount code FIRST20 saving new patients £20 on their first order.

When to Seek Professional Advice

While this article provides comprehensive and evidence-based information, it is not a substitute for personalised medical advice. You should speak to a healthcare professional before starting Mounjaro or any other weight management treatment, particularly in the following situations.

  • You have a personal or family history of thyroid cancer, pancreatitis, or multiple endocrine neoplasia syndrome.
  • You are currently pregnant, breastfeeding, or planning to become pregnant in the near future.
  • You are taking other medications that affect blood glucose, blood pressure, or thyroid function.
  • You have a history of eating disorders, including anorexia, bulimia, or binge eating disorder.
  • You experience any new or unexplained symptoms after starting Mounjaro, including persistent abdominal pain, vomiting, vision changes, or signs of a severe allergic reaction.
  • You are unsure whether your BMI and health profile meet the current eligibility criteria.

If you are experiencing any symptoms of concern, do not delay seeking medical attention. For non-urgent questions about your eligibility or suitability, the clinical team at Cured Pharmacy's weight loss service can guide you through the assessment process and help you make an informed, safe decision. Remember that responsible weight management is a long-term journey, not a quick fix, and the right support makes an enormous difference to long-term outcomes.

Scientific References

  1. NICE Technology Appraisal TA1026: Tirzepatide for managing overweight and obesity in adults, NICE, 2024 [Accessed 18 August 2026]
  2. MHRA: Mounjaro (tirzepatide) approved for weight management in adults, MHRA, 2023 [Accessed 18 August 2026]
  3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity, New England Journal of Medicine, 2022 [Accessed 18 August 2026]
  4. NICE Clinical Guideline CG189: Obesity: identification, assessment and management, NICE, 2014 (updated 2023) [Accessed 18 August 2026]
  5. Electronic Medicines Compendium (EMC): Mounjaro Summary of Product Characteristics (SmPC), Eli Lilly, 2023 [Accessed 18 August 2026]
  6. NHS: Obesity overview, causes, and treatment, NHS, 2023 [Accessed 18 August 2026]
  7. Diabetes UK: Tirzepatide (Mounjaro) information for patients, Diabetes UK, 2024 [Accessed 18 August 2026]
  8. British National Formulary (BNF): Tirzepatide drug monograph, NICE/BNF, 2024 [Accessed 18 August 2026]
  9. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo on glycaemic control in adults with type 2 diabetes, The Lancet, 2022 [Accessed 18 August 2026]
  10. UK Government: NICE decisions on tirzepatide for obesity, NICE/GOV.UK, 2024 [Accessed 18 August 2026]
  11. NHS: Semaglutide injection (Wegovy/Ozempic) overview, NHS, 2024 [Accessed 18 August 2026]
  12. Royal College of General Practitioners (RCGP): Guidance on prescribing weight management medications in primary care, RCGP, 2024 [Accessed 18 August 2026]
  13. General Pharmaceutical Council (GPhC): Standards for registered pharmacies and online dispensing, GPhC, 2023 [Accessed 18 August 2026]
  14. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes, New England Journal of Medicine, 2021 [Accessed 18 August 2026]
  15. MHRA: Mounjaro (tirzepatide) approved for weight management, MHRA Public Statement, 2023 [Accessed 18 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Frequently Asked Questions

Can you get Mounjaro for weight loss without diabetes in the UK?

Yes, you can get Mounjaro for weight loss without diabetes in the UK. Mounjaro received MHRA approval for weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related health condition, entirely separate from its use in type 2 diabetes. A clinical assessment from a registered prescriber is still required before any prescription is issued.

How long does Mounjaro take to show weight loss results?

Mounjaro typically takes between four to eight weeks to produce noticeable weight loss results. Most patients experience appetite reduction within the first two weeks as doses are titrated upward. The most significant weight loss tends to occur between weeks twelve and thirty-six, with clinical trial participants achieving an average of 22.5% body weight loss over 72 weeks at the highest dose.

Is Mounjaro safe to use if you do not have diabetes?

Mounjaro is considered safe for non-diabetic adults who meet the licensed eligibility criteria, based on extensive clinical trial evidence reviewed by the MHRA. The SURMOUNT-1 trial enrolled specifically non-diabetic participants and demonstrated a favourable safety profile. As with any medication, a prescriber must assess your individual health history, contraindications, and current medications before confirming suitability.

What is the starting dose of Mounjaro for weight loss?

The starting dose of Mounjaro for weight loss is 2.5 mg once weekly, administered as a subcutaneous injection. This initial dose is maintained for four weeks before increasing to 5 mg. Subsequent dose escalations occur in 2.5 mg increments every four weeks, up to a maximum of 15 mg weekly, allowing the body to adjust gradually and minimising gastrointestinal side effects such as nausea.

Back to blog